Trial Profile
A phase 3b, randomized, open-label, parallel group, multicenter trial assessing the efficacy of Exubera vs lispro introduced into a Lantus based regimen in suboptimally controlled patients with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine (Primary) ; Insulin lispro (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 26 Feb 2009 Actual patient number changed from 450 to 190 as reported by ClinicalTrials.gov.
- 26 Feb 2009 Actual end date changed from Jul 2008 to Aug 2008 as reported by ClinicalTrials.gov.
- 26 Feb 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.